Artificial Intelligence3 years ago
Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company“), a leader in the development of serotonergic psychedelic compounds, is pleased to...